Endometrial cancer therapy in 2026

Area of Science:

• Gynecology
• Oncology

Background:

• Endometrial cancer incidence is rising, highlighting the need for innovative diagnostic and therapeutic strategies.
• Recent years have seen significant advancements in understanding endometrial cancer biology and patient responses.

Purpose of the Study:

• To review recent developments in endometrial cancer diagnosis and treatment.
• To highlight novel approaches for managing endometrial cancer, including fertility preservation and immunotherapy.

Main Methods:

• Review of recent literature on endometrial cancer staging, biomarkers, and treatment modalities.
• Analysis of new therapeutic options, including immunotherapy and FDA-approved treatments for recurrent disease.

Main Results:

• Implementation of a revised staging system for endometrial cancer.
• Identification of biomarkers and factors influencing tumor biology and treatment efficacy.
• Advancements in fertility-preserving options for eligible patients.
• Extensive research into immunotherapy, including checkpoint inhibitors, for advanced or recurrent endometrial cancer.
• FDA approvals for new treatments have improved outcomes for recurrent endometrial cancer.

Conclusions:

• Significant improvements in endometrial cancer therapy have led to increased survival and better patient outcomes.
• Despite progress, unmet needs persist, requiring continued research and development beyond 2026.